Investors / France / Jeito Capital
Jeito Capital
Venture capital · France · Europe
Jeito Capital is an independent international investment firm focused on health and biopharma, with €1.6 billion in assets under management. It provides significant capital and operational support to biopharma companies across the drug development value chain, with teams in Europe and the United States.
Invests inHealthcare & Biotech
In its own wordsbiopharmatherapeuticsoncologyautoimmuneophthalmologycardiology
Your fit with Jeito Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsJeito Capital lists 20 checked portfolio companies on its own site and is named in 5 funding rounds, 3 of them as lead. Its most frequent entry is Series A, 60% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 31% of its companies are based in United States. It invests most often alongside Omega Funds, RA Capital and Catalio Capital Management.
Counts come from funding rounds that name Jeito Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Jeito Capital's whole history. Rounds on record name 5 companies; its own site lists 20. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundJeito Capital does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 60% |
| Series B | 0% |
| Growth | 40% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 0 |
| '26 | 3 | 3 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 51th | 20 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 95th | 25% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 88th | 7 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Omega Funds | 6 |
| RA Capital | 4 |
| Catalio Capital Management | 3 |
| Sanofi Ventures | 3 |
| Ysios Capital | 3 |
| AdBio partners | 2 |
| Avego | 2 |
| BioGeneration Ventures | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers1995%
- No longer answers00%
- Points to another company15%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Jeito Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Jeito Capital| Date | Company | Stage |
|---|---|---|
| 22 Jun 2026 | Series A Led | |
| 14 Apr 2026 | Series C+ Led | |
| 24 Feb 2026 | Series A Led | |
| 10 Sept 2025 | Series C+ | |
| 24 Mar 2025 | Series A |
Round details for Jeito Capital
Amounts, full round histories and every co-investor in Jeito Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
20 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Adcendo is developing a new generation of antibody-drug conjugates to address cancers with high unmet medical need. | Healthcare & Biotech | Apr 2026Series C+ | Page + round | |
| Advesya is transforming the fight against cancer and autoimmune diseases with unique IL-1RAP targeting approaches | Healthcare & Biotech | Portfolio page | ||
| Alentis Therapeutics is a clinical-stage biotech company that treats cancer and reverses fibrosis by developing anti-Claudin-1 antibody-drug conjugates and monoclonal antibodies | Healthcare & Biotech | Portfolio page | ||
| Alveus Therapeutics develops treatments for obesity and weight loss maintenance | Healthcare & Biotech | Feb 2026Series A | Page + round | |
| Augustine Therapeutics develops novel HDAC6 inhibitors for the treatment of chronic diseases | Healthcare & Biotech | Mar 2025Series A | Page + round | |
| Aviceda Therapeutics develops novel therapies to improve the lives of patients with immune-mediated diseases | Healthcare & Biotech | Portfolio page | ||
| Azafaros develops treatments for rare neurological diseases, including lysosomal storage disorders. | Healthcare & Biotech | Portfolio page | ||
| Bionyra Pharma is a clinical-stage biopharmaceutical company developing antibody therapies for immune-mediated inflammatory diseases such as atopic dermatitis and inflammatory bowel disease. | Healthcare & Biotech | Jun 2026Series A | Page + round | |
| Callio Therapeutics is a global, clinical-stage biotechnology company developing dual-payload antibody-drug conjugates (ADCs) to address the key limitation of current therapies, resistance. | Healthcare & Biotech | Portfolio page | ||
| CatalYm is developing a safe and efficacious immune therapy for solid tumors. | Healthcare & Biotech | Portfolio page | ||
| CDR-Life develops innovative treatments for cancer and autoimmune diseases through its T cell engager platform, M-gager | Healthcare & Biotech | Portfolio page | ||
| Corteria Pharmaceuticals is a privately held company developing first-in-class drugs for indications of high unmet medical need, such as obesity, heart failure subpopulations and autosomal dominant polycystic kidney disease | Healthcare & Biotech | Portfolio page | ||
| EyeBio is a subsidiary of Merck that develops therapies for eye diseases. | Healthcare & Biotech | Portfolio page | ||
| NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases. | Healthcare & Biotech | Portfolio page | ||
| Noema Pharma is a clinical-stage biotech developing oral small molecule therapeutics for neurological and related disorders. | Healthcare & Biotech | Portfolio page | ||
| Odyssey Therapeutics develops therapeutic candidates for autoimmune and inflammatory diseases | Healthcare & Biotech | Sept 2025Series C+ | Page + round | |
| Quell Therapeutics develops therapies designed to safely restore immune balance in patients with complex autoimmune diseases. | Healthcare & Biotech | Portfolio page | ||
| ReproNovo develops novel therapies for fertility and women’s health | Healthcare & Biotech | Portfolio page | ||
| SparingVision develops gene therapies for blinding retinal diseases. | Healthcare & Biotech | Portfolio page | ||
| XyloCor Therapeutics is focused on improving the lives of patients through our commitment to advancing novel therapies for coronary artery disease. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- jeito.life
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 24 Mar 2025
- Companies checked
- 20
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Jeito Capital's profile as data
Pull Jeito Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/jeito.life
# also
GET /v1/firms/jeito.life/portfolio
GET /v1/firms/jeito.life/coinvestors
GET /v1/firms/jeito.life/news